Affiance Financial LLC Increases Stock Holdings in Danaher Co. (NYSE:DHR)

Affiance Financial LLC boosted its holdings in Danaher Co. (NYSE:DHR) by 54.4% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,135 shares of the conglomerate’s stock after buying an additional 400 shares during the period. Affiance Financial LLC’s holdings in Danaher were worth $169,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in DHR. FMR LLC boosted its position in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after acquiring an additional 3,217,631 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares during the period. International Assets Investment Management LLC increased its holdings in shares of Danaher by 40,196.5% during the 3rd quarter. International Assets Investment Management LLC now owns 429,964 shares of the conglomerate’s stock worth $119,539,000 after buying an additional 428,897 shares during the last quarter. Montrusco Bolton Investments Inc. raised its position in shares of Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock worth $465,617,000 after buying an additional 397,671 shares during the period. Finally, Caisse DE Depot ET Placement DU Quebec boosted its holdings in Danaher by 82.4% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 653,375 shares of the conglomerate’s stock valued at $181,651,000 after acquiring an additional 295,187 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.1 %

Shares of Danaher stock opened at $245.95 on Friday. Danaher Co. has a twelve month low of $225.42 and a twelve month high of $281.70. The stock has a market capitalization of $177.65 billion, a price-to-earnings ratio of 46.94, a PEG ratio of 4.43 and a beta of 0.83. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The business’s 50 day simple moving average is $235.33 and its 200-day simple moving average is $253.45.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Stephens restated an “overweight” rating and issued a $315.00 price objective on shares of Danaher in a report on Wednesday, October 23rd. Barclays cut their price target on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Citigroup reduced their target price on shares of Danaher from $305.00 to $285.00 and set a “buy” rating on the stock in a report on Monday, January 6th. Finally, Raymond James decreased their price target on Danaher from $300.00 to $275.00 and set an “outperform” rating for the company in a report on Tuesday, January 21st. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.